Clinical and Experimental Neuroimmunology

Volume 12, Issue 3 pp. 148-149

NEW DEVELOPMENTS IN NEUROIMMUNOLOGY

Interleukin-19 ameliorates experimental autoimmune encephalitis

Hideyuki Takeuchi,

Corresponding Author

Hideyuki Takeuchi

[email protected]

orcid.org/0000-0001-5912-7581

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Correspondence: Hideyuki Takeuchi MD, PhD, Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine. Fukuura 3-9, Kanazawa-ku, Yokohama 236-0004, Japan.

Email: [email protected]

Search for more papers by this author

Hiroshi Horiuchi,

Hiroshi Horiuchi

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Search for more papers by this author

Bijay Parajuli,

Bijay Parajuli

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Search for more papers by this author

Hiroyasu Komiya,

Hiroyasu Komiya

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Search for more papers by this author

Fumiaki Tanaka,

Fumiaki Tanaka

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Search for more papers by this author

Akio Suzumura,

Akio Suzumura

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Search for more papers by this author

Hideyuki Takeuchi,

Corresponding Author

Hideyuki Takeuchi

[email protected]

orcid.org/0000-0001-5912-7581

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Correspondence: Hideyuki Takeuchi MD, PhD, Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine. Fukuura 3-9, Kanazawa-ku, Yokohama 236-0004, Japan.

Email: [email protected]

Search for more papers by this author

Hiroshi Horiuchi,

Hiroshi Horiuchi

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Search for more papers by this author

Bijay Parajuli,

Bijay Parajuli

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Search for more papers by this author

Hiroyasu Komiya,

Hiroyasu Komiya

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Search for more papers by this author

Fumiaki Tanaka,

Fumiaki Tanaka

Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Search for more papers by this author

Akio Suzumura,

Akio Suzumura

Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan

Search for more papers by this author

First published: 29 March 2021

https://doi.org/10.1111/cen3.12642

Share a link

Email
Wechat
Bluesky

Graphical Abstract

Interleukin-19 serves as a negative feedback regulator to limit the pro-inflammatory response of macrophages and microglia in autocrine/paracrine manners. Interleukin-19 suppresses microglia/macrophage antigen presentation, T helper 17 cell expansion and subsequent inflammation in the central nervous system, resulting in improvement in experimental autoimmune encephalomyelitis.